It’s complicated: Criteria for policy decisions for the clinical integration of genome-scale sequencing for reproductive decision making

Molecular Genetics and Genomic Medicine

Volumn 3, Issue 4, 2015, Pages 239-242

  Wilfond, Benjamin S ^a,b   Goddard, Katrina A B ^c  

^a SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c CENTER FOR HEALTH RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85008263976     PISSN: None     EISSN: 23249269     Source Type: Journal    
DOI: 10.1002/mgg3.130     Document Type: Note

References (15)

1. Biesecker, L. G., and R. C. Green. 2014. Diagnostic clinical genome and exome sequencing. N. Engl. J. Med. 371:1170.
2. Calvo, S. E, A. G. Compton, S. G. Hershman, S. C. Lim, D. S. Lieber, and E. J. Tucker. 2012. Molecular diagnosis of infantile mitochondrial disease with targeted next-generation sequencing. Sci. Transl. Med. 4(118):118ra10.
3. Dixon-Salazar, T. J., J. L. Silhavy, N. Udpa, J. Schroth, S. Bielas, and A. E. Schaffer. 2012. Exome sequencing can improve diagnosis and alter patient management. Sci. Transl. Med. 2012. 4(138):138ra78.
4. Grody, W. W., G. R. Cutting, K. W. Klinger, C. S. Richards, M. S. Watson, and R. J. Desnick. 2001. Laboratory standards and guidelines for population-based cystic fibrosis carrier screening. Genet. Med. 3:149–154.
5. Grody, W. W., B. H. Thompson, A. R. Gregg, L. H. Bean, K. G. Monaghan, A. Schneider, et al. 2013. ACMG position statement on prenatal/preconception expanded carrier screening. Genet. Med. 15(6):482–483.
6. Ioannou, L., B. J. McClaren, J. Massie, S. Lewis, S. A. Metcalfe, L. Forrest, et al. 2014. Population-based carrier screening for cystic fibrosis: a systematic review of 23 years of research. Genet. Med. 16(3):207–216.
7. Lazarin, G. A., I. S. Haque, S. Nazareth, K. Iori, A. S. Patterson, J. L. Jacobson, et al. 2013. An empirical estimate of carrier frequencies for 400+ causal Mendelian variants: results from an ethnically diverse clinical sample of 23,453 individuals. Genet. Med. 15(3):178–186.
8. Levy, H. L. 2014. Newborn screening: the genomic challenge. Mol. Genet. Genomic Med. 2:81–84.
9. Mennuti, M. T., E. Thomson, and N. Press. 1999. Screening for cystic fibrosis carrier state. Obstet. Gynecol. 93:456–461.
10. Mickle, J. E., and G. R. Cutting. 2000. Genotype-phenotype relationships in cystic fibrosis. Med. Clin. North Am. 84:597–607.
11. Modra, L. J., R. J. Massie, and M. B. Delatycki. 2010. Ethical considerations in choosing a model for population-based cystic fibrosis carrier screening. Med. J. Aust. 193:157–160.
12. Need, A. C., V. Shashi, Y. Hitomi, K. Schoch, K. V. Shianna, M. T. McDonald, et al. 2012. Clinical application of exome sequencing in undiagnosed genetic conditions. J. Med. Genet. 49(6):353–361.
13. Strom, C. M., D. Huang, A. Buller, J. Redman, B. Crossley, B. Anderson, et al. 2002. Cystic fibrosis screening using the college panel: platform comparison and lessons learned from the first 20,000 samples. Genet. Med. 4:289–296.
14. Wilfond, B. S., and K. Nolan. 1993. National policy development for the clinical application of genetic diagnostic technologies. Lessons from cystic fibrosis. JAMA 270:2948–2954.
15. Wilfond, B., and E. J. Thomson. 2000. Models of public health genetic policy development. Pp. 61–81 in M. Khoury, W. Burke and E. Thomson, eds. Genetics and public health in the 21st century: using genetic information to improve health and prevent disease. Oxford University Press, New York, NY.